The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America As Represented by the Department of Health

Medicenna Therapeutics, Inc.

University of Michigan

The United States of America As Represented by the Secretary of

The Penn State Research Foundation

Meshaberase, LLC

Raj K Puri

Ira H Pastan

Waldemar Debinski

Nicholas Obiri

Fahar Merchant

Robert J Kreitman

Bharatkumar H Joshi

Steven L Kunkel

Benjamin Morris Rubin

Ivan J Fuss

Warren Strober

Koji Kawakami

Cory Hogaboam

Atsushi Kitani

Syed R Husain

Kathryn C Zoon

Peter Mannon

Stefan Fichtner-Feigl

Claudia Jakubzick

Bharat Joshi

Daniel S Green

Jan Preiss

The present invention relates to interleukin-4 receptor-binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 or interleukin-13 protein moiety joined to an anti-apoptotic Bcl-2 family member protein moiety.

Interleukin-4 receptor-binding fusion proteins and uses thereof

The present invention relates to interleukin-4 receptor binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 receptor binding protein moiety joined to a pro-apoptotic Bcl-2 family member protein moiety.

The present Disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or a derivative thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.

Use of cysteamine and derivatives thereof to suppress tumor metastases

Methods and compositions are disclosed for treating a subject with a cancer. The compositions can include a chimeric molecule comprising an agent that specifically binds the interleukin 4 receptor (IL-4R) and a toxic moiety, an interferon alpha (IFN&#x3b1;), and an interferon gamma (IFN&#x3b3;). In some non-liming embodiments, the compositions can also include monocytes. The methods disclosed herein include administering a therapeutically effective amount of the compositions taught herein to a subject with cancer, thereby treating the cancer in the subject, wherein cells in the cancer express IL-4R. In some non-liming embodiments, the methods can also include administering monocytes.

Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer

The present invention combines a targeted cargo protein with an active agent for the treatment of a disease or condition.

Targeted cargo protein combination therapy

The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule to the NKT cells.

Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells

The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral, bacterial, fungal and parasitic infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.

Chimeric molecule for the treatment of th2-like cytokine mediated disorders

The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell bearing an IL-13 receptor. The method involves providing a chimeric molecule that comprises an effector molecule attached to a circularly permuted IL-13 (&ldquo;cpIL-13&rdquo;) that specifically binds an IL-13 receptor and contacting the tumor cell with the chimeric molecule. The compositions include chimeric molecules comprising effector molecules such as modified Pseudomonas exotoxin attached to a cpIL-13. The invention further provides vectors encoding the chimeric molecules.

IL-13 receptor specific chimeric proteins and uses thereof

The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule comprising an effector molecule attached to a targeting molecule that specifically binds an IL-13 receptor and contacting a tumor cell with the chimeric molecule in the presence of an interleukin-4 receptor (IL-4R) blocker.

Compositions and methods for specifically targeting tumors

Circularly permuted ligands and circularly permuted chimeric molecules

This invention provides chimeric molecules useful for killing tumor cells bearing IL13 receptor(s) (IL-13R). The molecules comprise a cytotoxic molecule attached to a targeting molecule that specifically binds an IL-13 receptor. Preferred targeting molecules include IL-13 and anti-IL-13R antibodies.

IL-13 receptor specific chimeric proteins

The present invention provides for circularly permuted ligands which possess specificity and binding affinity comparable to or greater than the specificity and binding affinity of the original (unpermuted) ligand. The invention further provides for novel fusion proteins comprising a circularly permuted ligand fused to one or more proteins of interest.

Fusion proteins comprising circularly permuted ligands

The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule that comprises an effector molecule attached to a targeting molecule that specifically binds an IL-13 receptor and contacting a tumor cell with the chimeric molecule.

Growing community of inventors

Potomac, MD, United States of America

Raj K Puri